Cat. No.: HY-N0597

Panaxatriol

3 Cited Publications

Customer Review

Based on 3 publication(s) in Google Scholar

Panaxatriol is an orally active dammarane-type tetracyclic triterpene sapogenin. Panaxatriol enhances the phosphorylation levels of Akt, insulin receptor and p70S6K in skeletal muscle. Panaxatriol reduces the mRNA expression level of Atrogin1 in skeletal muscle. Panaxatriol induces apoptosis, pre-G1 cell cycle arrest and increased intracellular ROS levels in prostate cancer cells, decreases mitochondrial membrane potential, inhibits cell migration and reduces colony formation. Panaxatriol can be used in research related to insulin resistance, myocardial ischemia/reperfusion injury and prostate cancer ^[1][2][3].

For research use only. We do not sell to patients.

Purity: 99.93%
CAS No.: 32791-84-7
Formula: C₃₀H₅₂O₄
Molecular Weight:476.73

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Panaxatriol Chemical Structure

CAS No.: 32791-84-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Akt Isoforms :

In Vitro

Panaxatriol (15-60 μM; 48-72 h) exhibits concentration-dependent cytotoxicity against DU-15 human prostate cancer cells, with an IC₅₀ of 30 μM^[3].
Panaxatriol (15-60 μM; 6 days) concentration-dependently suppresses colony formation by DU-15 human prostate cancer cells^[3].
Panaxatriol (15-60 μM; 48 h) concentration-dependently induces apoptosis in DU-15 human prostate cancer cells, as detected by DAPI staining^[3].
Panaxatriol (15-60 μM; 72 h) concentration-dependently increases intracellular ROS production in DU-15 human prostate cancer cells^[3].
Panaxatriol (15-60 μM; 72 h) concentration-dependently reduces mitochondrial membrane potential in DU-15 human prostate cancer cells^[3].
Panaxatriol (15-60 μM; 24 h) concentration-dependently induces sub-G1 cell cycle arrest in DU-15 human prostate cancer cells, with 24.8% of cells arrested at 60 μM^[3].
Panaxatriol (30 μM; 48 h) inhibits the migration of DU-15 human prostate cancer cells in an in vitro wound healing assay^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

DU-15 human prostate cancer cells
Concentration:

10 μM; 15 μM; 30 μM; 50 μM; 100 μM
Incubation Time:

48 h; 72 h
Result:

Exerted concentration-dependent cytotoxic effects on DU-15 cells, with an IC₅₀ of 30 μM.

Cell Cycle Analysis^[3]

Cell Line:

DU-15 human prostate cancer cells
Concentration:

15 μM; 30 μM; 60 μM
Incubation Time:

24 h
Result:

Induced sub-G1 cell cycle arrest in a concentration-dependent manner, with sub-G1 cell fractions reaching 10.4% at 15 μM, 17.3% at 30 μM, and 24.8% at 60 μM.

Cell Migration Assay^[3]

Cell Line:

DU-15 human prostate cancer cells
Concentration:

30 μM
Incubation Time:

48 h
Result:

Suppressed the migratory capability of DU-15 cells.

In Vivo

Panaxatriol (0.2% in standard diet; p.o.; daily; 6 weeks) supplementation alone improves insulin resistance markers and modulates muscle protein synthesis/degradation pathways in insulin-resistant KKAy mice, and when combined with aerobic exercise, it further reduces HOMA-R to 10.3, increases soleus muscle mass to 16.3 mg, and enhances Akt and p70S6K phosphorylation compared to exercise alone^[1].
Pretreatment with panaxatriol (5 mg/kg; p.o.; daily; 7 days) markedly ameliorates ischemia/reperfusion-induced myocardial damage in isolated rat hearts, as demonstrated by preserved cardiac contractile function, reduced myocardial enzyme leakage, attenuated oxidative stress, and delayed time to contracture^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

KK-Ay/Ta Jcl (KKAy) (6-week-old male, spontaneous insulin-resistant model)^[1]
Dosage:

0.2% (in standard diet)
Administration:

p.o.; daily; 6 weeks
Result:

Significantly reduced blood glucose.
Increased soleus muscle Akt phosphorylation to 1.5 arbitrary units (AU), normalized to GAPDH.
Increased p70S6K phosphorylation to 1.5 AU, normalized to GAPDH.
Reduced Atrogin1 mRNA expression levels.
Reduced HOMA-R to 10.3 when combined with aerobic exercise.
Increased soleus muscle mass to 16.3 mg.
Increased soleus myofiber cross-sectional area (CSA) significantly higher than exercise alone when combined with aerobic exercise.
Increased Akt phosphorylation to 2.3 AU when combined with aerobic exercise.

Animal Model:

Sprague-Dawley (male, 250-300 g, myocardial ischemia/reperfusion injury model via 30 min global ischemia + 30 min reperfusion after 7-day pretreatment)^[2]
Dosage:

5 mg/kg
Administration:

p.o.; once daily; 7 consecutive days
Result:

Increased post-reperfusion left ventricular developed pressure to 68.1 mmHg.
Reached a post-reperfusion double product of 12.8.
Significantly increased time to contracture compared with the vehicle-treated group.
Significantly lowered malondialdehyde (MDA) levels compared with the vehicle-treated group.
Significantly elevated reduced glutathione (GSH) levels compared with the vehicle-treated group.

Chemical Information

CAS No. 32791-84-7
Appearance Solid
Molecular Weight 476.73
Formula C₃₀H₅₂O₄
Color White to off-white
SMILES

C[C@@]1(CC[C@@H]2O)[C@](C[C@H]3O)([H])[C@](C[C@@H](O)[C@@]1([H])C2(C)C)(C)[C@@]4(C)[C@@]3([H])[C@]([C@](CCC5)(C)OC5(C)C)([H])CC4
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All

Sort by:

Journal Impact Factor

J Adv Res

Panaxatriol exerts anti-senescence effects and alleviates osteoarthritis and cartilage repair fibrosis by targeting UFL1. [Abstract]

2025 Aug:74:493-511. PMID: 39442872
Acta Pharmacol Sin

Ginsenoside (20)S-APPT induces ferroptosis in hepatocellular carcinoma and cholangiocarcinoma by targeting FSP1. [Abstract]

2025 Jun 23. PMID: 40550962
Planta Med

Discovery and characterization of panaxatriol as a novel thrombin inhibitor from Panax notoginseng using combination of computational and experimental approach. [Abstract]

2024 Aug;90(10):801-809. PMID: 38838717

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (52.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0976 mL

10.4881 mL

20.9762 mL

5 mM

0.4195 mL

2.0976 mL

4.1952 mL

10 mM

0.2098 mL

1.0488 mL

2.0976 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Takamura Y, et al. Effects of Aerobic Exercise Combined with Panaxatriol Derived from Ginseng on Insulin Resistance and Skeletal Muscle Mass in Type 2 Diabetic Mice. J Nutr Sci Vitaminol (Tokyo). 2017;63(5):339-348. [Content Brief]

[2]. Kim TH, et al. The effects of ginseng total saponin, panaxadiol and panaxatriol on ischemia/reperfusion injury in isolated rat heart. Food Chem Toxicol. 2010;48(6):1516-1520. [Content Brief]

[3]. Yu R, et al. Potential antitumor effects of panaxatriol against DU-15 human prostate cancer cells is mediated via mitochondrial mediated apoptosis, inhibition of cell migration and sub-G1 cell cycle arrest. J BUON. 2018;23(1):200-204. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0976 mL	10.4881 mL	20.9762 mL	52.4406 mL
	5 mM	0.4195 mL	2.0976 mL	4.1952 mL	10.4881 mL
	10 mM	0.2098 mL	1.0488 mL	2.0976 mL	5.2441 mL
	15 mM	0.1398 mL	0.6992 mL	1.3984 mL	3.4960 mL
	20 mM	0.1049 mL	0.5244 mL	1.0488 mL	2.6220 mL
	25 mM	0.0839 mL	0.4195 mL	0.8390 mL	2.0976 mL
	30 mM	0.0699 mL	0.3496 mL	0.6992 mL	1.7480 mL
	40 mM	0.0524 mL	0.2622 mL	0.5244 mL	1.3110 mL
	50 mM	0.0420 mL	0.2098 mL	0.4195 mL	1.0488 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Panaxatriol

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Terpenoids Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Drug-Resistant Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Panaxatriol

All Akt Isoforms

Biological Activity

Chemical Information

Publications (3)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs